Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
This is the complete answer, not a partial one — the list is never padded.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Christopher Kroeger | $655,250 | $0 | $12,296,267 | $12,322,406 | $331,000 | $0 | $19,331 | $25,624,254 |
| President and Chief Executive Officer | ||||||||
| Erin Foff | 531,000 | 0 | 2,871,478 | 2,636,670 | 194,000 | 0 | 20,851 | 6,254,000 |
| Chief Medical Officer | ||||||||
| Vishwas Setia | 432,294 | 0 | 3,200,500 | 2,367,617 | 183,000 | 0 | 19,153 | 6,202,564 |
| Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Christopher Kroeger | $25,624,254 | — | — | — |
| Erin Foff | 6,254,000 | — | — | — |
| Vishwas Setia | 6,202,564 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
No insider equity transactions reported since the proxy statement.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Christopher Kroeger | RSU | 853,459 | — | $14,991,007 |
| Vishwas Setia | RSU | 248,513 | — | 4,365,131 |
| Christopher Kroeger | RSU | 225,693 | — | 3,964,298 |
| Christopher Kroeger | RSU | 218,094 | — | 3,830,821 |
| Erin Foff | RSU | 206,901 | — | 3,634,216 |
| Christopher Kroeger | RSU | 94,017 | — | 1,651,409 |
| Vishwas Setia | RSU | 72,743 | — | 1,277,731 |
| Erin Foff | RSU | 57,155 | — | 1,003,928 |
| Christopher Kroeger | RSU | 56,204 | — | 987,223 |
| Erin Foff | RSU | 48,275 | — | 847,950 |
| Vishwas Setia | RSU | 43,367 | — | 761,741 |
| Erin Foff | RSU | 21,208 | — | 372,519 |
| Erin Foff | RSU | 11,335 | — | 199,099 |
| Christopher Kroeger | Option | 3,070 | 5.55 | — |
| Christopher Kroeger | Option | 916,164 | 17 | — |
| Vishwas Setia | Option | 176,031 | 17 | — |
| Erin Foff | Option | 82,619 | 5.55 | — |
| Erin Foff | Option | 1,290 | 5.55 | — |
| Erin Foff | Option | 196,035 | 17 | — |
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | — |
| Clawback policy | — |
| Anti-hedging | — |
| Anti-pledging | — |
| Ratio (CEO : median employee) | — |
|---|---|
| CEO total compensation | — |
| Median employee compensation | — |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Robert Malenka, M.D., Ph.DIndependent · Not standing for re-election | $7,363 | $1,192,533 | $1,877,755 | — | $139,999 | $3,217,650 |
| Maria WalkerIndependent · Audit (Chair) | 51,841 | 498,968 | 344,374 | — | 0 | 895,183 |
| Timothy Garnett, M.B.B.SIndependent · Compensation | 51,841 | 332,189 | 344,374 | — | 0 | 728,403 |
| Nanna Lüneborg, Ph.DIndependent · Audit · Compensation | 10,584 | 0 | 0 | — | 0 | 10,584 |
| George PavlovIndependent · Compensation | 9,663 | 0 | 0 | — | 0 | 9,663 |
| Jim Trenkle, Ph.DIndependent · Audit · Nominating and Corporate Governance (Chair) · Not standing for re-election | 0 | 0 | 0 | — | 0 | 0 |
| Christopher A. Kroeger, M.DEmployee director · Board Chair | — | — | — | — | — | 0 |
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $131,292 |
| Equity awards (grant-date value) | $2,023,690 |
| All other compensation | $139,999 |
| Total cost of the board | $2,294,981 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | MapLight Therapeutics | 2025 | Christopher Kroeger | $655,250 | $12,296,267 | $12,322,406 | $331,000 | $25,624,254 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Christopher Kroeger | DEF 14A | 2026-04-29 | 0001193125-26-191449 | Section “SUMMARY COMPENSATION TABLE”. As printed: 25,624,254. Filing ↗machine: r2 · c26 · span 218198–218208 |
| 2 | Section 01, Erin Foff | DEF 14A | 2026-04-29 | 0001193125-26-191449 | Section “SUMMARY COMPENSATION TABLE”. As printed: 6,254,000. Filing ↗machine: r6 · c26 · span 226904–226913 |
| 3 | Section 01, Vishwas Setia | DEF 14A | 2026-04-29 | 0001193125-26-191449 | Section “SUMMARY COMPENSATION TABLE”. As printed: 6,202,564. Filing ↗machine: r4 · c26 · span 222579–222588 |
| 4 | Section 07, pay ratio | 10-K | 2026-03-26 | 0001193125-26-125072 | Section “CEO Pay Ratio”. As printed: —. Filing ↗ |
| 5 | Section 08, Robert Malenka, M.D., Ph.D | DEF 14A | 2026-04-29 | 0001193125-26-191449 | Section “Director Compensation”. As printed: 3,217,650. Filing ↗machine: span 324377–324386 |
| 6 | Section 08, Maria Walker | DEF 14A | 2026-04-29 | 0001193125-26-191449 | Section “Director Compensation”. As printed: 895,183. Filing ↗machine: span 329307–329314 |
| 7 | Section 08, Timothy Garnett, M.B.B.S | DEF 14A | 2026-04-29 | 0001193125-26-191449 | Section “Director Compensation”. As printed: 728,403. Filing ↗machine: span 321002–321009 |
| 8 | Section 08, Nanna Lüneborg, Ph.D | DEF 14A | 2026-04-29 | 0001193125-26-191449 | Section “Director Compensation”. As printed: 10,584. Filing ↗machine: span 321556–321562 |
| 9 | Section 08, George Pavlov | DEF 14A | 2026-04-29 | 0001193125-26-191449 | Section “Director Compensation”. As printed: 9,663. Filing ↗machine: span 324920–324925 |
| 10 | Section 08, Jim Trenkle, Ph.D | DEF 14A | 2026-04-29 | 0001193125-26-191449 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 11 | Section 08, Christopher A. Kroeger, M.D | DEF 14A | 2026-04-29 | 0001193125-26-191449 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 12 | Section 09b board cost (computed) | Computed | — | computed | Cash 131,292 + equity 2,023,690 + all other 139,999 = 2,294,981, summed across the director compensation table rows.machine: formula: Σ = 2,294,981 |
| 13 | MapLight Therapeutics (subject), Section 10b CEO total | DEF 14A | 2026-04-29 | 0001193125-26-191449 | CEO total compensation as printed in MapLight Therapeutics's own proxy. As printed: 25,624,254. Filing ↗machine: r2 · c26 · span 218198–218208 |